Pinpoint Therapeutics believes that the company’s approach to treat therapy-resistant cancers also may be effective against COVID-19.
The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for hydroxychloroquine and chloroquine, long-used malaria drugs to treat the illness caused by the novel coronavirus.
